Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) have received an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $16.25.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a report on Wednesday, January 21st.

Cabaletta Bio Trading Down 4.2%

Shares of NASDAQ CABA opened at $2.97 on Thursday. Cabaletta Bio has a 1-year low of $0.99 and a 1-year high of $3.78. The company has a market cap of $285.89 million, a PE ratio of -1.17 and a beta of 3.25. The company has a 50-day moving average of $2.82 and a two-hundred day moving average of $2.50.

Insider Transactions at Cabaletta Bio

In other news, Director Shawn Tomasello bought 22,725 shares of the stock in a transaction dated Wednesday, January 21st. The stock was bought at an average cost of $2.21 per share, with a total value of $50,222.25. Following the purchase, the director owned 22,725 shares of the company’s stock, valued at approximately $50,222.25. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Steve Gavel bought 22,170 shares of the company’s stock in a transaction dated Wednesday, January 21st. The shares were purchased at an average price of $2.27 per share, with a total value of $50,325.90. Following the transaction, the insider owned 22,170 shares of the company’s stock, valued at $50,325.90. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 127,668 shares of company stock valued at $286,211 over the last 90 days. 11.25% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Catalyst Funds Management Pty Ltd acquired a new position in Cabaletta Bio in the second quarter valued at about $32,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Cabaletta Bio during the 4th quarter worth about $34,000. CRA Financial Services LLC increased its stake in shares of Cabaletta Bio by 36.4% in the 3rd quarter. CRA Financial Services LLC now owns 15,000 shares of the company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Cabaletta Bio in the 4th quarter valued at approximately $38,000. Finally, Clear Harbor Asset Management LLC bought a new position in Cabaletta Bio during the 4th quarter worth approximately $43,000.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.